To evaluate the contribution of hematologic factors and longterm inflammation to the development of myocardial infarction at a young age, we measured hematolo gic variables, including soluble fibrin and high-sensitivi...To evaluate the contribution of hematologic factors and longterm inflammation to the development of myocardial infarction at a young age, we measured hematolo gic variables, including soluble fibrin and high-sensitivity C-reactive protei n, in 90 patients who had myocardial infarction and 138 controls ≤45 years of a ge. Plasma levels of soluble fibrin and C-reactive protein were significantly h igher in patients than in controls. On multivariate regression analysis, soluble fibrin was the strongest predictor of myocardial infarction at a young age.展开更多
BACKGROUND: Previous trials have demonstrated that lowering low-density lipoprotein(LDL) cholesterol levels below currently recommended levels is beneficial in patients with acute coronary syndromes. We prospectively ...BACKGROUND: Previous trials have demonstrated that lowering low-density lipoprotein(LDL) cholesterol levels below currently recommended levels is beneficial in patients with acute coronary syndromes. We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter(2.6 mmol per liter) in patients with stable coronary heart disease(CHD). METHODS: A total of 10,001 patients with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter(3.4 mmol per liter) were randomly assigned to double-blind therapy and received either 10 mg or 80 mg of atorvastatin per day. Patients were followed for a median of 4.9 years. The primary end point was the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. RESULTS: The mean LDL cholesterol levels were 77 mg per deciliter(2.0 mmol per liter) during treatment with 80 mg of atorvastatin and 101 mg per deciliter(2.6 mmol per liter) during treatment with 10 mg of atorvastatin. The incidence of persistent elevations in liver aminotransferase levels was 0.2 percent in the group given 10 mg of atorvastatin and 1.2 percent in the group given 80 mg of atorvastatin(P< 0.001). A primary event occurred in 434 patients(8.7 percent) receiving 80 mg of atorvastatin, as compared with 548 patients(10.9 percent) receiving 10 mg of atorvastatin, representing an absolute reduction in the rate of major cardiovascular events of 2.2 percent and a 22 percent relative reduction in risk(hazard ratio, 0.78; 95 percent confidence interval, 0.69 to 0.89; P< 0.001). There was no difference between the two treatment groups in overall mortality. CONCLUSIONS: Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of atorvastatin per day. This occurred with a greater incidence of elevated aminotransferase levels.展开更多
文摘To evaluate the contribution of hematologic factors and longterm inflammation to the development of myocardial infarction at a young age, we measured hematolo gic variables, including soluble fibrin and high-sensitivity C-reactive protei n, in 90 patients who had myocardial infarction and 138 controls ≤45 years of a ge. Plasma levels of soluble fibrin and C-reactive protein were significantly h igher in patients than in controls. On multivariate regression analysis, soluble fibrin was the strongest predictor of myocardial infarction at a young age.
文摘BACKGROUND: Previous trials have demonstrated that lowering low-density lipoprotein(LDL) cholesterol levels below currently recommended levels is beneficial in patients with acute coronary syndromes. We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter(2.6 mmol per liter) in patients with stable coronary heart disease(CHD). METHODS: A total of 10,001 patients with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter(3.4 mmol per liter) were randomly assigned to double-blind therapy and received either 10 mg or 80 mg of atorvastatin per day. Patients were followed for a median of 4.9 years. The primary end point was the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. RESULTS: The mean LDL cholesterol levels were 77 mg per deciliter(2.0 mmol per liter) during treatment with 80 mg of atorvastatin and 101 mg per deciliter(2.6 mmol per liter) during treatment with 10 mg of atorvastatin. The incidence of persistent elevations in liver aminotransferase levels was 0.2 percent in the group given 10 mg of atorvastatin and 1.2 percent in the group given 80 mg of atorvastatin(P< 0.001). A primary event occurred in 434 patients(8.7 percent) receiving 80 mg of atorvastatin, as compared with 548 patients(10.9 percent) receiving 10 mg of atorvastatin, representing an absolute reduction in the rate of major cardiovascular events of 2.2 percent and a 22 percent relative reduction in risk(hazard ratio, 0.78; 95 percent confidence interval, 0.69 to 0.89; P< 0.001). There was no difference between the two treatment groups in overall mortality. CONCLUSIONS: Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of atorvastatin per day. This occurred with a greater incidence of elevated aminotransferase levels.
